Who/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010 [Date Accessed] Available at www.whointhpvcentre.
Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2(1):59–65.
Article
CAS
PubMed
Google Scholar
Martin CM, Kehoe L, Spillane CO, O'Leary JJ. Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers. Mol Diagn Ther. 2007;11(5):277–90.
Article
CAS
PubMed
Google Scholar
Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11 Suppl 1:24A–35A.
PubMed
Google Scholar
Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002;94(21):1604–13.
Article
CAS
PubMed
Google Scholar
Dobbs ME, Strasser JE, Chu CF, Chalk C, Milligan GN. Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms. J Virol. 2005;79(23):14546–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dockrell DH. Apoptotic cell death in the pathogenesis of infectious diseases. J Infect. 2001;42(4):227–34.
Article
CAS
PubMed
Google Scholar
Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75(6):1169–78.
Article
CAS
PubMed
Google Scholar
Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol. 2006;6(4):308–17.
Article
CAS
PubMed
Google Scholar
Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373(6513):444–8.
Article
CAS
PubMed
Google Scholar
Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327–30.
CAS
PubMed
Google Scholar
Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29(6):1183–8.
CAS
PubMed
Google Scholar
Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–8.
Article
CAS
PubMed
Google Scholar
Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003;103(2):221–5.
Article
CAS
PubMed
Google Scholar
Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006;12(18):5596–602.
Article
CAS
PubMed
Google Scholar
Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, et al. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008;83(1):220–2.
Article
CAS
PubMed
Google Scholar
Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med. 1998;187(11):1825–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peters AM, Kohfink B, Martin H, Griesinger F, Wormann B, Gahr M, et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol. 1999;27(5):868–74.
Article
CAS
PubMed
Google Scholar
Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999;18(25):3754–60.
Article
CAS
PubMed
Google Scholar
Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, et al. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999;59(13):3068–72.
CAS
PubMed
Google Scholar
Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76(6):969–76.
Article
CAS
PubMed
Google Scholar
Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96(13):1030–6.
Article
CAS
PubMed
Google Scholar
Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet. 2005;42(6):479–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chatterjee K, Dandara C, Gyllensten U, van der Merwe L, Galal U, Hoffman M, et al. A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. J Med Virol. 2010;82(12):2082–6.
Article
CAS
PubMed
Google Scholar
Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99(1):113–8.
Article
CAS
PubMed
Google Scholar
Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med. 2004;14(3):475–8.
CAS
PubMed
Google Scholar
Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas −670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004;112(6):1084–5.
Article
CAS
PubMed
Google Scholar
Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202(7):967–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer. 2007;121(11):2451–7.
Article
CAS
PubMed
Google Scholar
Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.
Article
PubMed
PubMed Central
Google Scholar
Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39(5):605–13.
Article
CAS
PubMed
Google Scholar
Cybulski C, Wokolorczyk D, Gliniewicz B, Sikorski A, Gorski B, Jakubowska A, et al. A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat. 2008;112(2):367–8.
Article
PubMed
Google Scholar
Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat. 2008;111(1):139–44.
Article
CAS
PubMed
Google Scholar
Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, et al. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008;29(12):1443–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, et al. CASP8 variants D302H and −652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer. 2008;98(8):1434–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res. 2008;14(10):3230–6.
Article
CAS
PubMed
Google Scholar
De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Barile M, Fortuzzi S, et al. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Res Treat. 2009;113(3):607–8.
Article
PubMed
Google Scholar
Ji G, Gu A, Hu F, Wang S, Liang J, Xia Y, et al. Polymorphisms in cell death pathway genes are associated with altered sperm apoptosis and poor semen quality. Hum Reprod. 2009;24(10):2439–46.
Article
CAS
PubMed
Google Scholar
Ni C, Ye Y, Wang M, Qian H, Song Z, Jia X, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with risk of coal workers' pneumoconiosis. J Toxicol Environ Health A. 2009;72(11–12):712–6.
Article
CAS
PubMed
Google Scholar
Wang M, Zhang Z, Tian Y, Shao J. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res. 2009;15(7):2567–72.
Article
CAS
PubMed
Google Scholar
Chatterjee K, Williamson AL, Hoffman M, Dandara C. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer. J Med Virol. 2011;83(4):630–6.
Article
CAS
PubMed
Google Scholar
Hoffman M, Cooper D, Carrara H, Rosenberg L, Kelly J, Stander I, et al. Limited Pap screening associated with reduced risk of cervical cancer in South Africa. Int J Epidemiol. 2003;32(4):573–7.
Article
CAS
PubMed
Google Scholar
Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control. 2003;14(5):485–95.
Article
PubMed
Google Scholar
Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70(2):425–34.
Article
PubMed
Google Scholar